LifeMD, Inc. (NASDAQ:LFMD - Get Free Report) CEO Justin Schreiber sold 25,000 shares of the company's stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $5.19, for a total value of $129,750.00. Following the completion of the transaction, the chief executive officer now directly owns 2,703,715 shares of the company's stock, valued at approximately $14,032,280.85. This trade represents a 0.92 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Justin Schreiber also recently made the following trade(s):
- On Monday, December 2nd, Justin Schreiber sold 25,000 shares of LifeMD stock. The stock was sold at an average price of $6.52, for a total value of $163,000.00.
LifeMD Trading Up 0.5 %
Shares of NASDAQ:LFMD traded up $0.03 during trading on Monday, reaching $5.78. The company's stock had a trading volume of 799,608 shares, compared to its average volume of 769,636. The firm's 50 day simple moving average is $5.50 and its two-hundred day simple moving average is $5.58. The company has a current ratio of 0.83, a quick ratio of 0.78 and a debt-to-equity ratio of 10.83. LifeMD, Inc. has a 12 month low of $3.99 and a 12 month high of $12.88. The stock has a market capitalization of $250.34 million, a PE ratio of -9.03 and a beta of 1.49.
Wall Street Analysts Forecast Growth
LFMD has been the topic of several research analyst reports. Cantor Fitzgerald reissued an "overweight" rating and issued a $15.00 target price on shares of LifeMD in a report on Friday, September 20th. HC Wainwright reissued a "buy" rating and set a $12.00 price objective on shares of LifeMD in a report on Monday, November 11th. Mizuho assumed coverage on LifeMD in a report on Wednesday, December 4th. They issued a "neutral" rating and a $7.00 target price on the stock. Finally, Lake Street Capital assumed coverage on LifeMD in a research note on Tuesday, December 10th. They set a "buy" rating and a $12.00 price target for the company. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $11.57.
Get Our Latest Stock Report on LFMD
Institutional Investors Weigh In On LifeMD
Institutional investors have recently modified their holdings of the stock. Los Angeles Capital Management LLC raised its holdings in LifeMD by 852.6% during the 3rd quarter. Los Angeles Capital Management LLC now owns 121,585 shares of the company's stock valued at $637,000 after buying an additional 108,822 shares during the period. State Street Corp increased its position in LifeMD by 20.0% during the third quarter. State Street Corp now owns 1,155,495 shares of the company's stock valued at $6,055,000 after acquiring an additional 192,861 shares during the last quarter. The Manufacturers Life Insurance Company purchased a new stake in shares of LifeMD in the second quarter valued at $93,000. Centiva Capital LP bought a new stake in shares of LifeMD in the 3rd quarter worth about $196,000. Finally, Royce & Associates LP boosted its stake in shares of LifeMD by 14.6% during the 3rd quarter. Royce & Associates LP now owns 901,041 shares of the company's stock worth $4,721,000 after purchasing an additional 114,710 shares during the period. 35.52% of the stock is owned by institutional investors.
About LifeMD
(
Get Free Report)
LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider LifeMD, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LifeMD wasn't on the list.
While LifeMD currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
